Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

CWA Asset Management Group LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 11.9% in ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

The case pits an employee's right to religious expression against the company's support of its LGBTQ+ workers.

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Versant Capital Management Inc increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 19.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,167 shares of the ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA.